NNMT Overexpression is an Adverse Prognostic Factor in Uterine Leiomyosarcoma

Overview

Journal Turk J Med Sci

Specialty General Medicine

Date 2024 Sep 19

PMID 39295619

Authors

Osman Turkmen

Kamil Hakan Muftuoglu

Nazmiye Dincer

Zeliha Esin Celik

Serra Akar Inan

Affiliations

Soon will be listed here.

Abstract

Background/aim: Uterine leiomyosarcomas (uLMS) are extremely rare high-grade tumors with a poor prognosis. Their etiopathogenesis remains largely unknown. The uterus is the most frequent site for LMS. uLMS and uterine leiomyoma (uLM) must frequently be differentiated in patients with a uterine mass. Nicotinamide N-methyltransferase (NNMT), a cytoplasmic protein, is involved in the progression and spread of a variety of cancer types. The expression of NNMT in a mesenchymal malignancy was not examined previously. This study represents the first investigation into NNMT expression in uLMS, uLM and benign uterine myometrium and correlates NNMT overexpression with worse prognosis in uLMS.

Materials And Methods: The expression of NNMT was investigated by immunohistochemistry on formalin-fixed paraffin-embedded tissue of uLMS in 31 patients, uLM in seven patients and benign myometrial in 31 patients.

Results: The expression of NNMT in uLMS was markedly higher than in uLM and normal myometrial tissue (p < 0.001). The expression of NNMT in early stage uLMS was lower than in advanced stage disease (p = 0.034). NNMT expression was an independent prognostic factor in predicting recurrence-free survival in uLMS (p = 0.037).

Conclusion: NNMT can aid in the preoperative differentiation of uLMS and uLM. The consequences of NNMT overexpression, such as the activation and inactivation of oncoproteins and tumor suppressor proteins, respectively, as well as the enrichment of the cancer stem cell population, overlap with the major mechanisms responsible for poor prognosis in mesenchymal tumors. NNMT may be investigated further in the context of antitumor treatment in patients with mesenchymal malignancies.

References

Feng Z, Guo S . Tim-3 facilitates osteosarcoma proliferation and metastasis through the NF-κB pathway and epithelial-mesenchymal transition. Genet Mol Res. 2016; 15(3). DOI: 10.4238/gmr.15037844. View

Byar K, Fredericks T . Uterine Leiomyosarcoma. J Adv Pract Oncol. 2022; 13(1):70-76. PMC: 8805803. DOI: 10.6004/jadpro.2022.13.1.6. View

Prat J . FIGO staging for uterine sarcomas. Int J Gynaecol Obstet. 2009; 104(3):177-8. DOI: 10.1016/j.ijgo.2008.12.008. View

Cuppens T, Tuyaerts S, Amant F . Potential Therapeutic Targets in Uterine Sarcomas. Sarcoma. 2015; 2015:243298. PMC: 4632006. DOI: 10.1155/2015/243298. View

Giuliani E, As-Sanie S, Marsh E . Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020; 149(1):3-9. DOI: 10.1002/ijgo.13102. View

Sannino G, Marchetto A, Kirchner T, Grunewald T . Epithelial-to-Mesenchymal and Mesenchymal-to-Epithelial Transition in Mesenchymal Tumors: A Paradox in Sarcomas?. Cancer Res. 2017; 77(17):4556-4561. DOI: 10.1158/0008-5472.CAN-17-0032. View

Chen Y, Guo Y, Yang H, Shi G, Xu G, Shi J . TRIM66 overexpresssion contributes to osteosarcoma carcinogenesis and indicates poor survival outcome. Oncotarget. 2015; 6(27):23708-19. PMC: 4695146. DOI: 10.18632/oncotarget.4291. View

Jour G, Scarborough J, Jones R, Loggers E, Pollack S, Pritchard C . Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics. Hum Pathol. 2014; 45(8):1563-71. DOI: 10.1016/j.humpath.2014.04.012. View

Akar S, Harmankaya I, Ugras S, Celik C . Nicotinamide N-methyltransferase expression and its association with phospho-Akt, p53 expression, and survival in high-grade endometrial cancer. Turk J Med Sci. 2019; 49(5):1547-1554. PMC: 7018241. DOI: 10.3906/sag-1907-166. View

10.

DAndrea F . Intrinsic radiation resistance of mesenchymal cancer stem cells and implications for treatment response in a murine sarcoma model. Dan Med J. 2012; 59(2):B4388. View

11.

Palanichamy K, Kanji S, Gordon N, Thirumoorthy K, Jacob J, Litzenberg K . NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability. Clin Cancer Res. 2016; 23(9):2325-2334. PMC: 5413402. DOI: 10.1158/1078-0432.CCR-16-1323. View

12.

Chen C, Wang X, Huang X, Yong H, Shen J, Tang Q . Nicotinamide N-methyltransferase: a potential biomarker for worse prognosis in gastric carcinoma. Am J Cancer Res. 2016; 6(3):649-63. PMC: 4851844. View

13.

Novak Kujundzic R, Prpic M, dakovic N, Dabelic N, Tomljanovic M, Mojzes A . Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer. Int J Mol Sci. 2021; 22(11). PMC: 8197977. DOI: 10.3390/ijms22115681. View

14.

Campagna R, Cecati M, Pozzi V, Fumarola S, Pompei V, Milanese G . Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. Cell Mol Biol (Noisy-le-grand). 2018; 64(7):51-55. View

15.

Song M, Li Y, Miao M, Zhang F, Yuan H, Cao F . High stromal nicotinamide N-methyltransferase (NNMT) indicates poor prognosis in colorectal cancer. Cancer Med. 2020; 9(6):2030-2038. PMC: 7064029. DOI: 10.1002/cam4.2890. View

16.

Kanska J, Aspuria P, Taylor-Harding B, Spurka L, Funari V, Orsulic S . Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget. 2017; 8(16):26200-26220. PMC: 5432250. DOI: 10.18632/oncotarget.15429. View

17.

Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y . MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014; 27(8):1144-53. PMC: 4081525. DOI: 10.1038/modpathol.2013.243. View

18.

Machado-Lopez A, Alonso R, Lago V, Jimenez-Almazan J, Garcia M, Monleon J . Integrative Genomic and Transcriptomic Profiling Reveals a Differential Molecular Signature in Uterine Leiomyoma versus Leiomyosarcoma. Int J Mol Sci. 2022; 23(4). PMC: 8877247. DOI: 10.3390/ijms23042190. View

19.

Xu Y, Liu P, Zheng D, Wu N, Zhu L, Xing C . Expression profile and prognostic value of NNMT in patients with pancreatic cancer. Oncotarget. 2016; 7(15):19975-81. PMC: 4991432. DOI: 10.18632/oncotarget.7891. View

20.

George S, Serrano C, Hensley M, Ray-Coquard I . Soft Tissue and Uterine Leiomyosarcoma. J Clin Oncol. 2017; 36(2):144-150. PMC: 5759317. DOI: 10.1200/JCO.2017.75.9845. View